Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Castle Biosciences, Inc. - Common stock
(NQ:
CSTL
)
40.77
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Castle Biosciences, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
January 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 25, 2023
Via
Benzinga
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
December 01, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
November 14, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
November 13, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
November 08, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Why Castle Biosciences Stock Is Jumping Today
↗
August 03, 2023
The genetic-testing company beat expectations with its Q2 results.
Via
The Motley Fool
Castle Biosciences to Present at Upcoming Investor Conferences
November 08, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
November 03, 2023
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 02, 2023
Via
Benzinga
Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
November 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Reports Third Quarter 2023 Results
November 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
October 24, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
October 19, 2023
From
Castle Biosciences Inc.
Via
Business Wire
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
October 18, 2023
From
Castle Biosciences Inc.
Via
Business Wire
DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
October 05, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
October 03, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
October 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
September 25, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
September 19, 2023
From
Castle Biosciences Inc.
Via
Business Wire
TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
September 14, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
September 12, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
September 09, 2023
From
Castle Biosciences Inc.
Via
Business Wire
TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus
September 08, 2023
From
Castle Biosciences Inc
Via
Business Wire
Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
September 06, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
September 05, 2023
From
Castle Biosciences Inc.
Via
Business Wire
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
August 07, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
↗
August 03, 2023
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90...
Via
Benzinga
Castle Biosciences Reports Second Quarter 2023 Results
August 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
